
In metastatic renal cell carcinoma (mRCC) and metastatic bladder cancer (mBC), palliative care focuses on life extension and quality rather than a cure. A study led by Hatice Bolek, MD, aimed to investigate patients’ perceptions of treatment outcomes in mRCC and mBC and how quality of life (QOL) and optimism influence these perceptions.
A multicenter, cross-sectional online survey of 169 patients was conducted from March 15, 2023, to January 15, 2024. The primary objective measures included patients’ perceptions of their disease’s curability and expected outcomes from treatment. Ninety-one patients (53.8%) had mRCC, and 78 (46.2%) had mBC.
The online survey included structured questions with Likert scale responses to assess perceptions of overall health status, disease cure, symptom improvement, daily activity performance, and life extension due to treatment. The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 version 3.0 was used to measure QOL, and the life orientation test was used to gauge optimism levels.